Pure Global
NCT06239727

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response: an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial
Sun Yat-sen University·Phase 3·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Nasopharyngeal Carcinoma
Drug/Device/Intervention
PD-1 blocking antibody
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Sun Yat-sen University
Location
Guangzhou,Zhongshan,Nanning,Guiyang,Wuhan,Wuhan,Changsha,Changsha, China
Timeline & enrollment
Phase
Phase 3
Start date
Feb 20, 2024
End date
Feb 20, 2030
Enrollment
593 participants
Primary outcome

Locoregional failure-free survival (LRFFS)

Summary

This is an Open Label, Non-Inferiority, Multicenter, Randomized Phase 3 Trial aimed to
 investigate the impact of reduced-dose radiotherapy in combination with chemotherapy and
 immunotherapy on patients' prognosis and complication compared with conventional-dose
 radiotherapy in combination with chemotherapy and immunotherapy for treatment-sensitive stage
 III NPC patients screened out according to the treatment response.

ICD-10 classifications
Malignant neoplasm of nasopharynxMalignant neoplasm: Nasopharynx, unspecifiedMalignant neoplasm: Overlapping lesion of nasopharynxBenign neoplasm: NasopharynxMalignant neoplasm: Posterior wall of nasopharynx
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06239727
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06239727 through Pure Global AI's free database. This Phase 3 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 593 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.